in the causal path to AD (Fig. 1). Notably, the minor allele of rs1057233 (G) is suggestively associated with lower AD risk (P=5.4×10−6, 5.9×10−7 in IGAP stage I, stage I and II combined, respectively)1, later AAO (P=8.4×10−6) and significantly associated with higher CSF Aβ42 (P=4.11×10−4), which likely reflects decreased Aβ aggregation and β-amyloid deposition in the brain. Furthermore, it is strongly associated with lower SPI1 expression in human monocytes (P=1.50×10−105) and macrophages (P=6.41×10−87, Table 3).
